

NAPCON KOLKATA 2026

HALL H1 | OCTOBER 30th | FRIDAY

ITC Royal - ITC Sonar

HALL H1 | OCTOBER 30th | FRIDAY

09:00-10:30	Symposium on COPD
09:00-09:20	Non-Tobacco Risk Factors for COPD
09:20-09:40	When the spirometry is preserved but lungs are not
09:40-10:00	COPD Pharmacotherapy: From Guidelines to Practice
10:00-10:30	Panel: COPD in India
10:30-11:30	Home NIV in chronic respiratory failure: ICS Guidelines
11:30-12:30	Orations
11:30-12:00	Oration 1
12:00-12:30	Oration 2
12:30-14:00	Symposium on ILD - The Royal Brompton Perspective
12:30-13:00	Keynote Address --Quantitative CT and lung physiology parameters underpin prognosis in ILD: the era is upon us
13:00-13:30	Keynote Address --IPF- diagnostics and antifibrotics therapy: What has changed and what has not?
13:30-14:00	Panel: Acute Exacerbations of ILD: How I manage it
14:00-15:00	Cardiovascular risk in respiratory diseases
14:00-14:15	Cardiac risk assessment in Lung diseases
14:15-14:30	Cardiovascular risk mitigation in COPD
14:30-14:45	CV risk reduction in OSA: Best strategy
14:45-15:00	Discussion
15:00-16:30	Managing Acute Respiratory Failure
15:00-15:30	HFNC vs. NIV in hypoxaemic respiratory failure
15:30-15:45	Awake proning in ICU: When and how?
15:45-16:00	Advances in ventilation for ARDS
16:00-16:30	Panel: Case based discussion on Acute Hypoxemic Respiratory Failure
16:30-17:30	Molecular Testing in Lung Cancer in India: from tissue stewardship to reflex NGS
16:30-16:45	Getting enough tissue and choosing the right assay

16:45-17:00	Reflex testing pathways in a public-hospital setting
17:00-17:15	Liquid biopsy: when plasma-first is good enough
17:15-17:30	Discussion
HALL H2 OCTOBER 30th FRIDAY	
09:00-10:30	From Periphery to Carina Frontiers of Interventional Pulmonology A World Association for Bronchology & Interventional Pulmonology (WABIP) master symposium
09:00-09:20	Reaching the peripheral nodule: robotic bronchoscopy, navigation and the diagnostic-yield decision
09:20-09:40	Emphysema - what is new? Bronchoscopic lung volume reduction in 2026
09:40-10:00	The malignant central airway: restoring the lumen in the next hour
10:00-10:30	Panel- From the peripheral nodule to the collapsing airway" - cases and controversies
10:30-11:30	COPD: Beyond Tobacco smoking
10:30-10:45	Post-TB lung disease: A Neglected Entity
10:45-11:00	Phenotyping COPD: Application of Etiotypes
11:00-11:15	Imaging in COPD: An Addition to Spirometry
11:15-11:30	Discussion
11:30-12:30	Debates
11:30-12:00	E-Cigarettes are legitimate harm reduction tools for smokers
12:00-12:30	The house believes that blood eosinophil count is the key biomarker for selecting biologic therapy
12:30-14:00	Pulmonary Function Tests
12:30-12:50	Interpretation of Spirometry
12:50-13:10	Utilizing DLCO and 6-minute walk test in clinical practice
13:10-13:30	Impulse oscillometry : Clinical utility
13:30-14:00	Panel- IOS and FOT: Current status
14:00-15:30	Remission in asthma: is it real?
14:00-14:20	Achieving remission in severe asthma: Myth or reality?
14:20-14:40	Early biologic use to modify disease
14:40-15:00	De-escalation after remission
15:00-15:30	Panel: Optimising Asthma Control

15:30-16:30	Tuberculosis
15:30-15:45	Advances in laboratory diagnosis of tuberculosis
15:45-16:00	Challenges in treatment of Drug Sensitive Tuberculosis
16:00-16:15	Treatment of mono-resistant tuberculosis
16:15-16:30	Discussion
16:30-17:30	Environment and airway diseases (University Of Maryland Symposium)
16:30-16:45	Occupational and Environmental Exposures: A Converging Threat to Respiratory Health
16:45-17:00	Evaluating Exposure-Related Lung Disease: From History Taking to Advanced Physiologic Assessment
17:00-17:15	Mechanisms and Health Consequences of Air Pollution and Occupational Exposures
17:15-17:45	Panel Discussion- Protecting respiratory health: personal choices, clinical action or public policy?
HALL H3 OCTOBER 30th FRIDAY	
09:00-10:30	Managing ILDs- sponsored by BI
09:00-09:20	Confident IPF diagnosis without biopsy: MDD, HRCT patterns & genomic classifiers
09:20-09:40	PPF in today's time: Right patient, Right therapy
09:40-10:00	Choice of antifibrotics in 2026
10:00-10:30	Panel — newer and combination anti-fibrotics
10:30-11:30	Pulmonary hypertension
10:30-10:45	Right-heart catheterisation & the new haemodynamic definitions
10:45-11:00	Correct classification before you treat
11:00-11:15	CTEPH: Beyond Anticoagulation — When to Operate, Dilate or Medicate?
11:15-11:30	Discussion
11:30-12:30	Year in Review: — the papers that should change your practice
11:30-11:50	Year in Review: Interstitial lung disease — the papers that should change your practice
11:50-12:10	Practice changing publications in COPD
12:10-12:30	Practice changing publications in asthma
12:30-14:00	PULMONARY VASCULITIS
12:30-12:45	Approach to the diagnosis of Pulmonary Vasculitis
12:45-13:00	Classifying and severity assessment of ANCA-Associated Vasculitis: a primer for pulmonologist

13:00-13:15	Contemporary management of ANCA Associated Vasculitis
13:15-13:30	Newer drugs in management of GPA
13:30-14:00	Panel: Contemporary management of pulmonary vasculitides
14:00-15:30	Pulmonary hypertension: Risk stratification and the case for upfront combination therapy
14:00-14:15	Multi-parametric risk assessment at diagnosis and every visit
14:15-14:30	Upfront dual vs triple therapy in PH: how aggressive and how soon?
14:30-14:45	The Diagnostic Grey Zone: Separating Group 1 PAH from Group 2 and Group 3 PH at the Bedside
14:45-15:00	The activin pathway (Sotarcept) era: a new dawn in Pulmonary hypertension
15:00-15:30	Panel- Advances in management of pulmonary hypertension
15:30-16:30	Hypersensitivity pneumonitis in India
15:30-15:45	Diagnosing hypersensitivity pneumonitis: Radiological evaluation
15:45-16:00	The exposure history and laboratory diagnosis: Identifying the right cause
16:00-16:15	Fibrotic vs non-fibrotic HP: immunosuppression, antifibrotics, or both
16:15-16:30	Discussion
16:30-17:30	Symposium on Pulmonary Embolism
16:30-16:45	Current Classification of Pulmonary Embolism
16:45-17:00	Newer anticoagulants: Have they replaced heparin
17:00-17:15	Choosing thrombolysis vs mechanical thrombectomy
17:15-17:30	Discussion
HALL H4 OCTOBER 30th FRIDAY	
09:00-10:30	Drug-resistant TB in 2026
09:00-09:20	MDR-TB Treatment in 2026: Challenges and Shortcomings
09:20-09:40	BPaL / BPaLM: Choosing the right patient
09:40-10:00	Building individualised regimen when the short course fails
10:00-10:30	Panel - Winning the fight against DR TB : Bridging diagnostic, drug resistance and treatment (GOI panel)
10:30-11:30	ERS State of the Art: Contemporary Challenges in Respiratory Medicine

10:30-11:00	Pleural infection updates: trials, guidelines and practice changing evidences
11:00-11:30	ERS Presidential address: Challenges in prevention of COPD Exacerbation
11:30-12:00	Keynote Address
12:00-12:30	Debate: Latent TB should be actively screened for and treated in India
12:30-14:00	Pleural Diseases
12:30-12:50	Investigating low ADA Exudative Pleural Effusion
12:50-13:10	Intricacies of Managing Chylothorax
13:10-13:30	Managing malignant Pleural Effusion: Pleurodesis vs IPC
13:30-13:45	Bronchopleural fistula: Surgeon's role
13:45-14:00	Discussion
14:00-15:30	Lung Cancer Symposium
14:00-14:20	Assessing driver mutations in Lung Cancer
14:20-14:40	Current staging for non-small cell lung cancer
14:40-15:00	The Surgeon's Dilemma in Lung Cancer: Curative Resection or Palliative Intervention?
15:00-15:30	Lung Cancer Case Based MDD: Pulmonologist, Pathologist, Surgeon, Radiotherapist and oncologist
15:30-16:30	Latent TB in the era of biologics, transplant and immunosuppression: whom to treat before you suppress
15:30-15:45	Methods of diagnosing LTBI
15:45-16:00	Choosing regimens for LTBI in the era of drug resistance
16:00-16:15	Current status of vaccines for tuberculosis
16:15-16:30	Discussion
16:30-17:30	The pulmonary infection in the immunocompromised host
16:30-16:45	Assessing immune status of patient with recurrent lower respiratory tract infections
16:45-17:00	Invasive fungal infections in the immunocompromised host

17:00–17:15	Treating fungal pneumonias: Current evidence
17:15–17:30	Discussion
HALL H5 OCTOBER 30th FRIDAY	
09:00–10:30	Diagnosing Peripheral Pulmonary Nodule
09:00–09:20	Radial-EBUS, navigation and cone-beam CT: what each adds to yield
09:20–09:40	Radiation safety in bronchoscopy Suite
09:40–10:00	navigating lung nodules: Evolving role of radiology and pulmonology in this era
10:00–10:30	Panel - Peripheral pulmonary nodule care across borders: Indian and global perspective
10:30–11:30	Chronic cough
10:30–11:00	KEYNOTE ADDRESS_- Treatment of unexplained chronic cough: Do we finally have an answer?
11:00–11:30	Panel- Chronic Cough: What Not to Miss — Red Flags, Mimics and Diagnostic Clues
11:30–14:00	ENVIRONMENT, AIR POLLUTION AND HEALTH
11:30–11:50	Assessing impact of air pollution on human Health
11:50–12:10	Air purifiers and Masks: Evidence of Benefit
12:10–12:30	National Air quality standards in India: A compromise?
12:30–13:00	Panel - Discussion Strategies for mitigating air pollution in India
14:00–15:30	Resectable NSCLC in 2026
14:00–14:20	Neoadjuvant and adjuvant chemo-immunotherapy: Current evidence and practice
14:20–14:40	TKIs in Resectable NSCLC: Role and Evidence
14:40–15:00	Following up a lung cancer patient after resection
15:00–15:30	Panel - Clearance for lung resection surgery: How to do it?
15:30–16:30	EBUS mastery: systematic staging and getting molecular-grade tissue in one pass
15:30–15:45	Systematic nodal staging: the sequence that prevents understaging
15:45–16:00	ROSE, sample handling and molecular testing for lung Cancer
16:00–16:15	EBUS beyond cancer: Sarcoidosis, lymphoma and infection
16:15–16:30	Discussion

16:30–17:30	Immunotherapy in Lung Cancer: What a pulmonologist should know?
16:30–16:45	PD-L1, and TMB: Who not to give IO to?
16:45–17:00	Checkpoint pneumonitis: recognising, grading and treatment
17:00–17:15	IO in the older / comorbid patient: the frailty conversation
17:15–17:30	Discussion
HALL H6 OCTOBER 30th FRIDAY	
09:00–10:30	OSA beyond the AHI: phenotyping the patient
09:00–09:30	KEYNOTE Address
09:30-09:50	Reading PSG: Beyond AHI
09:50-10:10	Non CPAP options in OSA: Choosing wisely
10:10–10:30	Panel — non-severe OSA: who to treat with PAP therapy?
10:30-11:30	Beyond the Scope: From Judgment to Advanced Intervention
10:30-11:00	Line Between Enthusiasm and Wisdom in Bronchoscopy- Cleaveland Talk
11:00-11:20	Beyond the Bronchoscope: Advanced Techniques for Difficult Central Airway Lesions
11:20-11:30	The Art & Science of Difficult Bronchoscopy: An Interactive Q&A
11:30-13:00	Infections in Pulmonary and Critical Care
11:30-11:50	The New Face of Community-Acquired Pneumonia: Biomarkers, Rapid Diagnostics and Novel Approaches
11:50-12:10	Rational Choice of Antibiotics in CAP
12:10-12:30	Corticosteroids for Severe Pneumonia: Controversy settled?
12:30-13:00	DEBATE: The CABP Crossroads- Conventional Limits vs Novel Innovation
13:00-14:30	SARCOIDOSIS
13:00-13:20	Granulomatous inflammation: Beyond TB and sarcoidosis

13:20-13:40	Extrapulmonary sarcoidosis: Approach
13:40-14:00	Paradigm shift in sarcoidosis management
14:00-14:30	Panel: Improving long term outcomes in sarcoidosis
14:30-16:00	Breathing at Work: The Hidden Burden of Occupational Lung Disease in India
14:30-14:50	what are causal factors of respiratory death and hospitalizations in India: ICS - SWORD survey
14:50-15:10	Asbestos related lung diseases: An under-recognised entity
15:10-15:30	Treating pneumoconiosis: Current and upcoming therapeutics
15:30-16:00	Panel: Preventing Occupational lung diseases in India
16:00-16:30	KEYNOTE- address
	Where we heal matters- Home Rehab vs Facility Care
16:30-17:30	Hemoptysis
16:30-16:45	Evaluation of patient with hemoptysis
16:45-17:00	Management of massive hemoptysis: Interventional Pulmonologist's role vs Surgeon's role
17:00-17:30	Panel discussion-Hemoptysis: Bronchoscopy, Embolization or Surgery — Who Goes First?

NAPCON KOLKATA 2026
HALL H1 | OCTOBER 31st | SATURDAY
ITC Royal - ITC Sonar

HALL H1 | OCTOBER 31st | SATURDAY

09:00-10:30	ARDS in 2026
09:00-09:20	Hyper- vs hypo-inflammatory ARDS: treating the phenotype, not the syndrome
09:20-09:40	Lung protective ventilation in ARDS: Applying the evidence
09:40-10:00	Prone, paralysis, ECMO: sequencing the rescue therapies
10:00-10:30	Panel — Rescue therapies in ARDS with refractory hypoxemia

10:30–11:30	Small-cell and the neuroendocrine spectrum: has anything really changed?
10:30–10:45	Limited-stage SCLC: chemo-RT, IO and the survivorship gain
10:45–11:00	Managing Extensive-stage SCLC
11:00–11:15	Carcinoids and large-cell NEC: surgical nuance
11:15–11:30	Discussion
11:30–12:30	ORATIONS
11:30–12:00	Oration 3
12:00–12:30	Oration 4
12:30–14:00	Bronchiectasis Unravelling: From Epidemiology to Evidence-Based Care
12:30–12:50	Epidemiology of Bronchiectasis in India: how do we differ?
12:50–13:10	Working up a bronchiectasis patient
13:10–13:30	Evidence based management of non-CF adult bronchiectasis
13:30–14:00	Panel - Beyond Antibiotics: Changing the Way We Manage Bronchiectasis
14:00–15:30	Asthma symposium
14:00–14:20	Triggers that matter in India: From festival smoke to thunderstorms
14:20–14:40	GINA 2026: What is new?
14:40–15:00	Severe Eosinophilic Asthma: choosing the right biologic?
15:00–15:30	Panel: Contemporary management of asthma in India
15:30–16:30	ULTRASOUND IN Pulmonary Medicine
15:30–15:45	Lung in POCUS
15:45–16:00	Cardiac and venous ultrasound in emergency
16:00–16:15	Hemodynamic assessment using Ultrasound
16:15–16:30	Discussion
16:30–17:30	Breath, Comfort, Dignity- A symposium on palliative care in pulmonology
16:30–16:45	Taming refractory breathlessness: the palliative toolkit for advanced lung disease
16:45–17:00	Home, not hospital: domiciliary support and the ceiling-of-care decision
17:00–17:15	Dying well with lung disease: advance care planning and the Indian legal framework
17:15–17:30	Discussion

HALL H2 OCTOBER 31st SATURDAY	
09:00-10:30	COPD: Triple therapy and beyond
09:00-09:20	LABA/LAMA vs triple therapy in COPD: who needs the ICS?
09:20-09:40	Newer inhaled drugs in COPD
09:40-10:00	The other face of COPD: lessons from the Himalayas
10:00-10:30	Panel discussion (30m) — Nebulised therapy and its use in stable COPD
10:30-11:30	Uncontrolled asthma: The checklist before you escalate
10:30-10:45	Is it really asthma-Confirming the diagnosis
10:45-11:00	When good medicines fail: The Critical role drug delivery
11:00-11:15	Untangling Comorbidities in asthma
11:15-11:30	Q&A (15m)
11:30-12:30	Key Note Address
11:30-12:00	Key Note Address: Remission and Precision in Severe Asthma: do we walk the talk?
12:00-12:30	Key Note Address: The Indian Paradox- COPD in never smokers
12:30-13:30	KEYNOTE- EMBARC frontiers in respiratory medicine: Shaping the future of precision care
12:30-13:00	From orphan disease to global diversity: the Embarc journey
13:00-13:30	Management of NTM-PD: Disease refractory to Guideline based Therapy
13:30-15:00	AI in the chest clinic
12:30-12:50	The Dawn of AI in Pulmonary Medicine: X-rays and CT Nodule Analysis
12:50-13:10	Ethical Considerations in deploying AI in Respiratory Practice
13:10-13:30	AI in Chronic Respiratory Diseases
13:30-14:00	Panel- Using AI in clinical practice: Panel Discussion
15:00-16:30	Diagnosing TB you can't culture
14:00-14:20	Molecular-first diagnostics (Ultra, targeted NGS): reading the discordant result
14:20-14:40	Extrapulmonary TB: tissue, imaging and the empirical decision

14:40–15:00	The subclinical / incipient TB controversy: to treat or to follow
15:00–15:30	Panel — Diagnosis of TB in current times
16:30-17:30	Overlap syndromes
16:30-16:45	OSA and COPD overlap syndrome
16:45-17:00	Asthma and COPD Co-existence: What is the reality?
17:00-17:15	COPD with ILD: How to manage?
17:15-17:30	Discussion
HALL H3 OCTOBER 31st SATURDAY	
09:00–10:30	CTD-ILD: multidisciplinary management
09:00 - 09:20	Screening the connective-tissue patient for ILD: who, how often, which test
09:20–09:40	Immunosuppression backbone: MMF vs rituximab vs cyclophosphamide
09:40–10:00	Adding antifibrotic to immunosuppression: the SSc-ILD and RA-ILD playbook
10:00–10:30	Panel - The CTD-ILD Dilemma: Screen, Suppress or Slow the Fibrosis?
10:30–11:30	Lung transplant referral: getting the timing right — not too early, never too late
10:30–10:45	Disease-specific referral windows for lung transplant evaluation
10:45–11:00	Absolute vs relative contraindications in 2026
11:00–11:15	Preparing the patient and the family for the pathway
11:15–11:30	Discussion
11:30-12:30	Viral Pneumonia 2.0: new threats , new tests , new challenges
11:30-11:45	Adult RSV: the disease we ignored and the new vaccines
11:45-12:00	Influenza antivirals: who, when and does it changes outcome
12:00-12:15	Management of Severe Viral Pneumonia
12:15-12:30	Discussion
12:30-14:00	Bronchiectasis: Beyond the Basics
12:30-12:50	Frequent Exacerbator Phenotype: Breaking the Cycle

12:50-13:10	Adult Cystic Fibrosis Bronchiectasis: What Can We Learn?
13:10-13:30	The Microbiome of Bronchiectasis: From Dysbiosis to Disease
13:30-14:00	Panel- The Future of Bronchiectasis: New Phenotypes, New Targets, New Treatments
14:00-15:30	Pleural effusion in 2026
14:00-14:20	Hepatic hydrothorax: managing the unmanageable
14:20-14:40	IPC vs talc pleurodesis for malignant effusion: How to choose?
14:40-15:00	Intrapleural fibrinolysis: is streptokinase still relevant
15:00-15:30	Panel — Recurrent pleural effusions- diagnostic dilemmas and treatment strategies
15:30-17:00	Leadership symposium- From MoUs to Meaningful Collaboration: Research, Education, and Equitable Partnerships Between ICS, ERS, ATS, APSR, EMBARC, and APACI
17:00-17:30	CONSENSUS STATEMENT ON SITT IN SEVERE ASTHMA (ZYDUS)
HALL H4 OCTOBER 31st SATURDAY	
09:00-10:00	Managing tropical pneumonias
09:00-09:15	Syndromic approach to tropical pulmonary infections
09:15-09:30	Scrub typhus ARDS: recognising the rickettsial cause early
09:30-09:45	Leptospirosis & the pulmonary-haemorrhage syndrome
09:45-10:00	Discussion
10:00-11:00	PGI Chandigarh Symposium: The Changing Face of Pulmonary Fungal Disease in the Indian Lung
10:00-10:15	ABPA in 2026: ISHAM-ABPA criteria, itraconazole and where biologics fit
10:15-10:30	Chronic pulmonary aspergillosis: diagnosis, antifungal choice and duration
10:30-10:45	Invasive mould disease in the non-neutropenic host: COVID, TB, ICU and beyond
10:45-11:00	Discussion
11:00-12:00	Managing Group 3 PH
11:00-11:15	Distinguishing 'proportionate' from severe Group 3 PH
11:15-11:30	Inhaled treprostinil in Group III PH
11:30-11:45	Adjunct therapies in group 3 PH

11:45-12:00	Discussion
12:00-12:30	Pro-Con Debate: NIV has a place in ARDS Management
12:30-14:00	DS TB Management
12:30-12:50	Challenges of NTEP implementation in India
12:50-13:10	Shortening the regimens for DSTB
13:10-13:30	Managing Adverse Drug Reactions during TB Treatment
13:30-14:00	Panel Discussion
14:00-15:30	ATS MECOR Session: case-based lectures
	Advances in asthma management: translating evidence into practice (case-based)
	Practical approach to progressive fibrosing ILD (case-based)
	Transforming TB diagnosis: emerging technologies and clinical applications (case-based)
	Discussion
15:30-16:30	DR TB Management
15:30-15:45	Molecular diagnostics in DR TB Management
15:45-16:00	Managing latent TB in the era of DR TB
16:00-16:15	Outcomes of Programmatic MDR TB Management
16:15-16:30	Discussion
16:30-17:30	Contemporary topics
16:30-16:45	Social Media and misinformation: How to handle?
16:45-17:00	Drug-induced lung diseases: Neglected all the time
17:00-17:15	Improving lung health through lifestyle and nutrition
17:15-17:30	Discussion
HALL H5 OCTOBER 31st SATURDAY	

09:00–10:30	Driver-positive advanced NSCLC
09:00–09:20	EGFR based therapies: combinations and managing resistance
09:20–09:40	ALK, ROS1 and the rare drivers: choosing and re-biopsying
09:40–10:00	Implementing lung cancer molecular diagnostics: challenges in India
10:00–10:30	Panel - Managing Driver-positive lung cancer
10:30–11:30	Pleural infection: The empyema pathway from first tap to surgery
10:30–10:45	Early risk stratification and the drainage decision
10:45–11:00	Intrapleural tPA/DNase: who, when and how
11:00–11:15	When medical therapy fails: timing the surgical referral
11:15–11:30	Q&A (15m)
11:30–12:30	GRAND ROUNDS- Walking the tight rope
	Multi Disciplinary tumor board: 2 cases - ILD and cancer
12:30–14:00	APACI–ICS Symposium: adult respiratory immunisation — closing the prevention gap
12:30–12:50	The influenza prevention gap: why are we still missing the vaccine opportunity?
12:50–13:10	Adult respiratory vaccination: national programme perspectives
13:10–13:30	Protecting the aging lung : Future of adult respiratory immunisation in SE asia
13:30–14:00	Panel— building adult vaccination into the chest clinic
14:00–15:30	NYU Langone – ICS Session: thoracic oncology, disaster medicine and career development
14:00–14:15	The New York City 2020 COVID Experience and What it Taught us
14:15–14:30	When Demand Exceeds Capacity: Ethical and Practical Lessons in Ventilator Allocation
14:30–14:45	Bronchoscopic treatment of peripheral lung cancer in 2027 and beyond
14:45–15:00	Surgery for NTM: Indications and Results

15:00-15:30	Open discussion (30 min) — career development, training and a sustainable respiratory workforce
15:30-16:30	ANTIBIOTICS IN ICU
15:30-15:50	NOVEL ANTIBIOTICS IN INDIAN SPECTRUM
15:50-16:10	Big Data in ICU
16:10-16:30	Navigating the maze of Carbapenemase alphabets
16:30-17:30	Fit to Fly, Dive & Climb: Pulmonary Fitness for Extreme Environments
16:30-16:45	Fitness to Fly — Pulmonary Assessment for Air Travel
16:45-17:00	Diving Medicine — Pulmonary Contraindications to Scuba
17:00-17:15	High Altitude Fitness — Physiology and Risk Stratification
17:15-17:30	Discussion
HALL H6 OCTOBER 31st SATURDAY	
09:00-10:30	Precision COPD Management
09:00-09:20	Treatable traits in COPD
09:20-09:40	Emerging biomarkers in COPD: Do they make a difference?
09:40-10:00	Young COPD: how to evaluate and manage
10:00-10:30	Panel: Precision therapy for COPD: The time has come
10:30-11:30	OSA Unplugged: New Targets, New Drugs, New Possibilities
10:30-10:45	Drugs for OSA: how to tackle the pathophysiology?
10:45-11:00	Excessive sleepiness on CPAP: Do drugs help?
11:00-11:15	Anti-obesity therapies for OSA: Hope or hype?
11:15-11:30	Beyond the Upper Airway: Is the Diaphragm the Missing Link in OSA?

12:00-13:30	Sleep Medicine Symposium
12:00-12:20	Cognitive Behavioral Therapy for Insomnia
12:20-12:40	Hypersomnolence: Evaluation and Management
12:40-13:00	REM related sleep disorders
13:00-13:30	Panel Discussion: Managing insomnia in sleep medicine
13:30-14:00	Keynote Address
	The Ten Commandments of TB: Principles That Should Never Be Broken
14:00-15:30	When Medicine Meets Its Limits: Ethics, Choices and Compassion in Advanced Lung Disease
14:00-14:15	When Cure Is No Longer the Goal: Ethics and Palliative Care in Advanced Lung Disease
14:15-14:30	Resource Allocation and End-of-Life in Respiratory Failure
14:30-15:30	Panel- Case-based discussion on ethical dilemmas
15:30-16:30	Defining severity of COPD exacerbation; what is new?
15:30-15:45	Managing COPD exacerbation in 2026
15:45-16:00	The COPD discharge bundle: How do I use it?
16:00-16:15	Home NIV after hypercapnic exacerbation
16:15-16:30	Discussion
16:30-17:30	Pulmonary hypertension
16:30-16:45	Pulmonary Hypertension: A Diagnostic Enigma
16:45-17:00	Group 3 PH: Are we missing the treatable vascular disease
17:15-17:30	Discussion

NAPCON KOLKATA 2026

HALL H1 | NOVEMBER 1st | SUNDAY

ITC Royal - ITC Sonar

HALL H1 | NOVEMBER 1st | SUNDAY

09:00-10:00	The Chest in the Clinic Practical Pulmonology for the Family Physician- meeting point of pulmo and
09:00-09:15	Screen, scan, stratify- An early diagnosis approach to CTD-ILD
09:15-09:30	Cough, Breathlessness, Shadow on X-ray: Manage or Refer?
09:30-10:00	Beyond the Lungs: Nutrition, Mood, Sarcopenia and the Systemic Burden of Chest Disease- panel
10:00 -10:30	SLEEP CONSENSUS STATEMENT
10:30-11:30	Interstitial lung abnormalities: the incidental finding you must not ignore — or over-treat
10:30-10:45	ILA vs early ILD: what the radiologist should flag
10:45-11:00	Following up a patient with ILA
11:00-11:15	Managing ILAs: clinical and radiological considerations
11:15-11:30	Discussion
11:30-13:00	When the Air Turns Hostile Respiratory Care in Disaster and Mass-Casualty
11:30-11:45	Blast, burn and toxic smoke: reading the lung in the first hour of a mass-casualty scene
11:45-12:00	Chemical and CBRN respiratory threats: chlorine, phosgene and nerve agents at the front line
12:00-12:15	Rehearsing the disaster: simulation-based training for the mass-casualty respiratory even
12:15-12:30	The outbreak is the disaster: biocontainment and critical care for the next high-consequence respiratory pathogen
12:30-13:00	"A respiratory mass-casualty arrives at your hospital tomorrow — are you ready?"
13:00-14:30	Severe asthma: choosing the right strategy

13:00-13:20	Mepolizumab vs benralizumab vs tezepelumab: how to match mechanism to phenotype
13:20-13:40	Response Assessment on Biologic Therapy: Switch, Stop or Re-phenotype?
13:40-14:00	Allergen Immunotherapy: On the Horizon?
14:00-14:30	Panel discussion (30m) — Panel: Asthma Staging — GINA and Its Caveats: Do Symptoms, Lung Function & Exacerbations Tell the Whole Story?
HALL H2 NOVEMBER 1st SUNDAY	
09:00-10:30	South Asian Respiratory Forum (ICS · SLCP · Nepal · Bangladesh · Maldives)
09:00-09:20	South EastAsia's respiratory disease paradox: infectious burden, chronic disease rise and climate driven risk
09:20-09:55	The Double Burden of Respiratory Disease in South Asia: Can We Tackle Infection and Chronic Disease Together?
09:55-10:30	Beyond Genes and Pollution: Understanding the South Asian Phenotype of Chronic Respiratory Disease
10:30-11:30	Early Identification of lung diseases
10:30-10:45	Early Identification of Lung Cancer: Catching the Disease Before It Is Too Late"
10:45-11:00	Early Identification of COPD: Finding the Disease Before the Symptoms
11:00-11:15	Early Identification of ILD: Recognising the Lung Before Irreversible Damage
11:15-11:30	Discussion
11:30-13:00	The physiology of getting off the ventilator: a weaning pathway that works
11:30-11:50	Readiness testing beyond the SBT: what actually predicts success
11:50-12:10	Diaphragm ultrasound for weaning decisions
12:10-12:30	Early vs late Tracheostomy: Role in weaning
12:30-13:00	Panel Discussion: Early mobilisation in ICU
13:00-13:30	Debate: Impulse oscillometry is an essential part of PFT laboratory
13:30-14:30	Translating GINA into the Indian clinic
13:30-13:45	ICS-formoterol as reliever: the evidence and the pharmacy reality

13:45-14:00	Mild asthma is not benign: exacerbation risk in 'infrequent' symptoms
14:00-14:15	Applicability of GINA in Indian settings
14:15-14:30	Discussion
HALL H3 NOVEMBER 1st SUNDAY	
09:00-10:00	Decoding OSA Phenotypes : from mechanisms to personalised therapy
09:00-09:20	OSA Phenotyping from PSG
09:20-09:40	OSA Phenotyping from DISE
09:40-10:00	Non-Obstructive OSA phenotype management
	Panel-Unravelling the PSG report
10:00-10:30	Redefining Pulmonary Rehabilitation: From Centre-Based Care to Home
10:00-10:15	Setting up a Pulmonary Rehabilitation Centre
10:15-10:30	Beyond the Rehabilitation Centre: Bringing Pulmonary Rehabilitation Home
10:30-12:00	CTD ILD Management
10:30-10:45	Laboratory evaluation of suspected CTD ILD patients
10:45-11:00	Radiology in CTD ILD
11:00-11:15	Drug therapies for SSc related ILD
11:15-11:30	Managing myositis associated ILD
11:30-12:00	Panel Discussion: Improving outcomes in CTD ILD
12:00-13:30	ILD Symposium
12:00-12:20	Predictors of progression in IPF
12:20-12:40	Managing cough and fatigue in ILDs
12:40-13:00	Dilemma of managing ILD in ICU
13:00-13:30	Panel discussion: Improving QoL in ILD patients
13:00-14:30	Sarcoidosis: Contemporary Management?
13:00-13:45	Sarcoidosis: When to treat? Asymptomatic vs organ-threatening: the treatment threshold
13:45-14:00	Steroid-sparing agents in sarcoidosis
14:00-14:15	The India question: is it sarcoid or is it TB?

14:15-14:30	Discussion
HALL H4 NOVEMBER 1st SUNDAY	
09:00-10:30	NTM
09:00-09:20	NTM in India: do we need a registry?
09:20-09:40	Diagnostics and emerging therapeutics for NTM
09:40-10:00	NTM in bronchiectasis- colonization, infection or disease
10:00-10:30	Panel- To treat or not to treat: a case based approach
10:30-11:30	Post-TB Sequelae: the epidemic after the cure that no one is funding
10:30-10:45	Spectrum of PTLD
10:45-11:00	Managing PTLD
11:00-11:15	Extrapulmonary Sequelae of TB
11:15-11:30	Discussion
11:30-13:00	The Sepsis Spectrum
11:30-11:50	Assessing severity and risk stratification
11:50-12:10	The sepsis- AKI nexus
12:10-12:30	Paradigm shift in fluid therapy in last decade
12:30-13:00	Panel Discussion-Choosing empiric antibiotics in the Indian setting: Is it different from the West?
13:00-14:00	Central airway obstruction
13:00-13:15	The Obstructed Central Airway: Stent, Dilate or Debulk?
13:15-13:30	
13:30-13:45	Anticipating and handling complications
13:45-14:00	Discussion

HALL H5 | NOVEMBER 1st | SUNDAY

09:00-10:30	How I do it?
09:00-09:20	Assessment for fitness to fly
09:20-09:40	Sleep scoring
09:40-10:00	Skin prick test
10:00- 10:20	FeNO
10:20-10:30	Discussion
10:30-11:30	Lung cancer screening for India
10:30-10:45	Risk models beyond pack-years: capturing the Indian non-smoker
10:45-11:00	Incidental nodule pathways as a pragmatic first step
11:00-11:15	LDCT Screening: Infrastructure and false-positive reality
11:15-11:30	Discussion
11:30-13:00	Pulmonary Manifestations of CTD
	Spectrum of CTD-ILD patterns, phenotypes and prognosis
	Therapeutic strategies- immunosuppressants, antifibrotics and 2025 guidelines
	The great mimickers: overlap syndrome, Drug-induced ILD and diagnostic pitfalls
	Navigating the ERS/EULAR 2026 guidelines: what's new
	Panel- CTD-ILD conundrum: Navigating complex cases
13:00-14:30	The Pulmo-Surgical Interface: Managing Airway & Pleural Disease
12:30-13:00	Managing tracheal stenosis: Pulmonologist perspective vs surgeon perspective
13:00-13:30	Primary Spontaneous pneumothorax management: Pulmonologist Perspective vs surgeon perspective
13:30-14:00	Panel- Persistent Air Leak: When Should the Pulmonologist Hand Over to Surgery?
14:30-15:30	Reducing the Volume, Improving the Function: Modern LVR Strategies
14:00-14:15	Selecting the right patient and the modality

14:15-14:30	Choosing the LVR technique- is Surgery better?
14:30-14:45	Bronchoscopic thermal vapour ablation for LVR: Does it work?
14:45-15:00	Discussion
HALL H6 NOVEMBER 1st SUNDAY	
09:00-10:30	SLEEP DISORDERS BEYOND OSA
09:00-09:20	Central Sleep Apnea: From Mechanisms to Modern Management
09:20-09:40	Comorbid Insomnia and Sleep Apnea
09:40-10:00	Deciphering Restless Leg Syndrome
10:00-10:30	Panel Discussion: Promoting Sleep Health
10:30-12:00	The wheezy child who isn't just asthmatic: sorting the pre-school phenotypes
10:30-10:45	Viral vs multi-trigger wheeze: when to start controllers
10:45-11:00	Red flags for the non-asthma diagnosis (aspiration, structural, immune)
11:00-11:15	The India context: TB, post-infectious and environmental drivers
11:15-11:30	Panel- The Wheezy Preschooler: Asthma, Phenotype or Something Else?
14:00-15:00	Post-viral breathlessness: a pragmatic work-up for the breathless survivor
14:00-14:15	Sorting the causes: parenchymal, vascular, dysfunctional breathing, deconditioning
14:15-14:30	What to investigate and what to reassure
14:30-14:45	Rehabilitation & the natural history conversation
14:45-15:00	Discussion